Today: 8 February 2026
Subscribe
Browse Category

Stock Market News 30 December 2025

Coca-Cola stock slips as Fed minutes hit thin year-end trade; KO investors eye next catalyst

Coca-Cola stock slips as Fed minutes hit thin year-end trade; KO investors eye next catalyst

NEW YORK, December 30, 2025, 3:25 PM ET — Regular session Coca-Cola shares edged lower on Tuesday, holding near $70 as investors kept risk-taking limited in thin, year-end trading. The quiet tape matters because Coca-Cola is a classic defensive stock. When markets get choppy, investors often rotate into consumer staples — everyday products like food and beverages — for steadier demand and cash returns. It also matters now because interest-rate expectations are back in focus. Dividend-paying shares can lose relative appeal when bond yields rise, since investors can earn more in cash-like alternatives without taking equity risk. Coca-Cola was down
30 December 2025
··
TIC Solutions (TIC) stock slides 3.5% today as Fed minutes and thin year-end trade set the tone

TIC Solutions (TIC) stock slides 3.5% today as Fed minutes and thin year-end trade set the tone

NEW YORK, December 30, 2025, 15:14 ET — Regular session Shares of TIC Solutions, Inc. (TIC) fell about 3.5% to $10.02 in afternoon trading on Tuesday, underperforming a largely steady U.S. equity market. The stock last closed at $10.38. The decline came in holiday-thin trade as investors recalibrated rate expectations after the Federal Reserve’s December-meeting minutes hit the tape. “At the end of the day, solid corporate profits can make up for a lot of sins,” said Ryan Detrick, chief market strategist at Carson Group. Reuters The slide matters for TIC because investors have been focused on execution rather than
30 December 2025
··
Applied Materials stock slips as China’s 50% domestic chip-tool rule puts AMAT in the spotlight

Applied Materials stock slips as China’s 50% domestic chip-tool rule puts AMAT in the spotlight

Applied Materials shares fell 1.1% to $260.27 Tuesday after Reuters reported China now requires chipmakers expanding capacity to source at least 50% of equipment domestically. The iShares Semiconductor ETF was little changed. Wells Fargo raised its price target on Applied Materials to $290 and maintained an Overweight rating. Lam Research and KLA shares also slipped about 1%.
30 December 2025
·····
Qualcomm stock edges up as Fed minutes hit; QCOM eyes Feb. 4 earnings call

Qualcomm stock edges up as Fed minutes hit; QCOM eyes Feb. 4 earnings call

NEW YORK, December 30, 2025, 15:14 ET — Regular session Qualcomm (QCOM.O) shares were up about 0.2% at $173.75 in afternoon trading on Tuesday, hovering near Monday’s close as markets digested new details on the U.S. interest-rate outlook. That matters for Qualcomm and other semiconductor names because investors often value them like “growth” stocks, whose prices can swing when bond yields move. In year-end trading, the rate narrative can outweigh company-specific headlines. Minutes from the Federal Reserve’s Dec. 9-10 meeting — the detailed account of policymakers’ debate — showed officials split even after approving a quarter-point, or 0.25 percentage point,
30 December 2025
····
Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals shares fell 3% to $23.33 in thin afternoon trading Tuesday, extending a two-day slide and leaving the stock about 12% below its June high. Biotech ETFs underperformed the broader market, with the iShares Nasdaq Biotechnology ETF down 1.2%. Investors are awaiting the Federal Reserve’s meeting minutes and Catalyst’s next update in January.
30 December 2025
··
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics shares fell 3% to $77.94 Tuesday afternoon, underperforming a 1.4% drop in the SPDR S&P Biotech ETF. The decline follows December’s $692 million equity raise and positive Phase 1b data for its STAT6 degrader KT-621. The stock traded about 9% below its recent $86 offering price. Investors are watching for updates on trial progress and cash burn ahead of 2026 milestones.
30 December 2025
··
Nebius stock slips today after CEO files to sell shares — what traders are watching next

Nebius stock slips today after CEO files to sell shares — what traders are watching next

NEW YORK, December 30, 2025, 15:09 ET — Regular session Nebius Group N.V. shares slipped on Tuesday after a regulatory filing showed chief executive Arkady Volozh plans to sell a small block of stock around year-end. SEC+1 The disclosure matters because Nebius has become a closely watched AI infrastructure name, where investors have been quick to react to any potential increase in share supply. Year-end trading can amplify moves, as fewer shares changing hands can push prices around. SEC Form 144 is the SEC notice insiders file when they intend to sell “control” securities, typically ahead of the actual transactions.
30 December 2025
·
Almonty Industries stock today: ALM slips as CBS report spotlights U.S. tungsten supply deal

Almonty Industries stock today: ALM slips as CBS report spotlights U.S. tungsten supply deal

Almonty Industries shares fell 3.9% to $8.90 Tuesday after early gains, trading between $8.90 and $9.39. The drop followed news that CEO Lewis Black met U.S. officials and signed a deal tied to future tungsten supply from the Sangdong mine in South Korea, which is set to start production in early 2026. Almonty recently raised $129.4 million in a U.S. share sale and delivered its first ore to Sangdong’s staging area.
30 December 2025
···
Why Western Digital stock is down today: WDC slides as year-end rotation cools AI-hardware trades

Why Western Digital stock is down today: WDC slides as year-end rotation cools AI-hardware trades

Western Digital shares fell 1.7% to $176.55 Tuesday, reversing early gains and underperforming storage peers in thin year-end trading. The stock, up 303% in 2025, has been volatile amid portfolio reshuffling and investor focus on Fed policy signals. No company news was tied to the drop. Broader U.S. indexes were little changed.
30 December 2025
···
Lululemon stock slips today as founder Chip Wilson launches proxy fight over board shake-up

Lululemon stock slips today as founder Chip Wilson launches proxy fight over board shake-up

Lululemon shares slipped 0.6% to $211.30 after founder Chip Wilson launched a proxy fight for board seats. The board said it will review Wilson’s nominees and issue a recommendation before the 2026 annual meeting. The move follows CEO Calvin McDonald’s decision to step down Jan. 31, with two executives named interim co-CEOs. Wilson holds a 4.27% stake and is acting alone, according to Reuters.
30 December 2025
·
Texas Instruments stock today: TXN flat after ReRAM licensing deal as Fed minutes land

Texas Instruments stock today: TXN flat after ReRAM licensing deal as Fed minutes land

Texas Instruments shares hovered near $176 after Weebit Nano licensed its ReRAM memory technology to the chipmaker for embedded processing chips. The stock slipped 0.01% to $175.67 in afternoon trading. The deal covers IP licensing and technology transfer, with Weebit’s ReRAM qualified for automotive-grade reliability. Trading volume was muted as investors digested the Fed’s latest meeting minutes.
30 December 2025
··
Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

NEW YORK, December 30, 2025, 14:45 ET — Regular session Arcutis Biotherapeutics shares fell 2.9% to $27.74 in afternoon trading on Tuesday, after moving between $27.72 and $28.65. Volume was about 0.6 million shares. The drop outpaced broader biotech gauges, with the SPDR S&P Biotech ETF down about 1.5% and the iShares Nasdaq Biotechnology ETF off about 1.1%. That matters for Arcutis because it trades as a growth story tied to one product franchise, leaving the stock prone to outsized moves when sentiment sours across biotech and high-multiple names. Arcutis is a commercial-stage medical dermatology company whose main product, Zoryve
30 December 2025
·
1 … 563 564 565 566 567 … 1,179

Stock Market Today

Shell share price in focus after Kazakhstan investment pause and PwC audit switch

Shell share price in focus after Kazakhstan investment pause and PwC audit switch

8 February 2026
London, Feb 8, 2026, 07:59 GMT — Market closed Shell Plc will pause new investments in Kazakhstan as legal disputes with the government drag on, Chief Executive Wael Sawan said. “We will hold until we have better line of sight to where things end up,” he told analysts. Kazakhstan alleges $13 billion and $3.5 billion in disputed costs at the Kashagan and Karachaganak oilfields, and one arbitration award could total $2 billion to $4 billion, sources have said. (Reuters) Shell’s London-listed shares (SHEL.L) last closed at 2,774.5 pence on Friday, up 5 pence, or 0.18%. With markets shut for the
RELX share price slides again on AI worries; what to watch ahead of Feb 12 results

RELX share price slides again on AI worries; what to watch ahead of Feb 12 results

8 February 2026
RELX shares fell 4.6% to 2,145p on Friday, near a 52-week low, despite the FTSE 100 closing higher. The company disclosed a new buyback of 465,361 shares on Feb. 6 and has repurchased over 8.8 million shares since Jan. 2. Investors await RELX’s full-year 2025 results on Feb. 12 amid concerns over AI’s impact on its core business.
Glencore shares steady after Rio walks away — what to watch before Monday’s trade

Glencore shares steady after Rio walks away — what to watch before Monday’s trade

8 February 2026
Glencore shares closed up 0.6% at 478.10 pence Friday after Rio Tinto ended merger talks, issuing a “no intention to bid” statement. Glencore’s board rejected the proposed deal terms, citing concerns over valuation and governance. Attention now turns to possible asset sales, including its $5 billion Kazzinc stake, ahead of Glencore’s annual results on Feb. 18.
Go toTop